White House Moves to Take Control of N.I.H. Grants

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-20T18:30:12.375Z • Permanent link

Federal officials are drafting an executive order that would place grants under review by an outside panel, according to multiple sources within the National Institutes of Health (NIH). The move is part of a broader effort to redirect billions of dollars in research spending, and it's being spearheaded by a team led by Eric Lander, the NIH's director. Lander, a renowned geneticist and expert in data science, has been a vocal advocate for greater transparency and accountability in the research process.

According to insiders, the executive order would establish a new review panel that would assess grant applications for scientific merit, efficiency, and alignment with NIH priorities. The panel would be composed of experts from various fields, including medicine, engineering, and computer science, and it would provide detailed feedback to grantees on their proposals. The move is seen as a significant shift in the NIH's approach to funding research, and it could have far-reaching implications for the scientific community.

Critics of the move argue that it would stifle innovation and limit the freedom of researchers to pursue their own ideas. "This is a classic case of bureaucratic overreach," said Dr. Francis Collins, the former NIH director and a vocal critic of the plan. "We need to be careful not to strangle the very system that's supposed to drive scientific progress." Despite these concerns, proponents of the plan argue that it's necessary to ensure that research dollars are being spent wisely and that the NIH is getting the best return on its investment.

The impact of this move will be felt across a range of industries and research communities. For companies like Illumina and Illumina, which provide sequencing technology and other research tools to scientists, the NIH's funding priorities will have a direct impact on their business models. "If the NIH is shifting its focus towards more applied research, that could lead to more funding for projects that have clear commercial potential," said Dan Wahls, a research analyst at Piper Jaffray. "But it could also limit the amount of funding available for basic research, which is often the most innovative and groundbreaking work.

Researchers at institutions like Stanford and MIT will also be affected by the move. Many of these researchers rely heavily on NIH funding to support their research, and a shift in the NIH's priorities could limit their access to funding. "This is a huge concern for us," said Dr. Andrew Fire, a Nobel laureate and director of the Stanford Center for Synthetic Biology. "We need to make sure that the NIH is supporting the types of research that are going to drive progress in our field.

The NIH's shift in funding priorities is part of a larger pattern of change in the research landscape. In recent years, there has been a growing emphasis on applied research and commercialization, as well as a focus on diversity and inclusion. The NIH has also been working to improve its data management and analytics capabilities, in part to support the growing demand for data-driven research.